drugset / Trial / NCT00788073
Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X Syndrome
RandomizedCrossoverQuadruple-blindTreatment
Summary
The study objective is to explore the efficacy, safety and tolerability of STX209 for treatment of irritability in subjects with FSX. We hypothesize that STX209 will improve irritability and other typical problem behaviors associated with fragile X syndrome. We also hypothesize that STX209 will be safe and well tolerated.
Timeline
- Start
- 2008-11
- Primary completion
- 2010-03
- Completion
- 2010-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Arbaclofen | Small molecule | 1 mg | Oral |
| Comparator | Arbaclofen | Small molecule | 10 mg | Oral |